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Chronic neuroinflammation has been observed to be a key factor in the progress of neurodegenerative 
diseases including Alzheimer’s disease (AD). Microglia serve as resident macrophages within the central 
nervous system (CNS) and become activated upon contact with entities that are released from dying neurons 
during neurodegenerative processes, these include neuro-filaments, Aβ aggregates and tau containing 
neurofibrillary tangles, exposed naked DNA and oligodendrocytic myelin fragments(1-3). This prompts 
microglial and astrocyte activation which ultimately causes further neuronal damage including synaptic 
depredation. Neuronal tissue within the central nervous system can become particularly vulnerable to chronic 
neuroinflammation as a vicious self-perpetuating cycle of inflammation causes chronic neuronal decay. It is 
thought that preventing and or reducing chronic neuroinflammation by anti-inflammatory drugs will reduce 
chronic neuroinflammation, thus disrupting the cycle of microglial and astrocyte activation and resulting 
neurodegeneration. 
This thesis compares the short and long-term anti-inflammatory properties of two drugs: The nootropic 
drug Tenilsetam (±)-3-(2-thienyl)-2-piperazinone (CAS 997, Tenilsetam) and the herbal spice curcumin 
(1E,6E)-1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (by Verdure Sciences) in the 
GFAP-IL6 mouse model.  
It was hypothesised that GFAP-IL6 mice fed with either Tenilsetam or Longvida curcumin will exhibit 
a decrease in total microglial numbers in the cerebellum and/or hippocampus. 
The first part of this thesis examines the short, and long-term effects of Tenilsetam fed to C57/B6 and 
GFAP-IL6 mice (three months old) for 5 or 15 months respectively and thereafter analysed just after treatment 
at 8 and 18 months respectively. Total number of TSPO+ and Iba-1+ microglia were measured in the 
cerebellum and hippocampus via stereological counting and used to help quantify inflammation rate as well 




The second portion of the project investigated the effects of Longvida curcumin on the Iba-1+ microglia 
in the cerebellum. Mice at 3 months of age were fed with food pellets for 5 months. The total number of Iba-
1+ microglia was measured via stereological counting and used to help quantify inflammation rate and were 
then compared to 8-month-old Tenilsetam fed GFAP-IL6 mice tested with Iba-1. 
Firstly, in the Tenilsetam cohort, the GFAP-IL6 control group showed to have a statistically 
significantly higher number of Iba-1+ and TSPO+ microglia in the cerebellum and hippocampus of 8 and 18-
month-old mice when compared to the C57/B6 control group. Tenilsetam showed to decrease total Iba-1+ 
microglia in the cerebellum and hippocampus at 8 months of age and a decrease of microglial population in 
the cerebellum at 18 months of age in GFAP-IL6 treated mice. The density of microglia in the cerebellum of 
GFAP-IL6 mice decreased to similar levels after 5 and 15 months of Tenilsetam feeding and cerebellar volume 
loss halted by Tenilsetam at 8 months of age in GFAP-IL6 mice. Tenilsetam showed to decrease total numbers 
of microglia in the hippocampus and cerebellum of GFAP-IL6 mice, this supports the claim that Tenilsetam 
has anti-inflammatory properties when fed to transgenic mice. 
Secondly, in the Longvida curcumin cohort, the GFAP-IL6 control mice showed to have a statistically 
significantly higher number of Iba-1+ microglia in the cerebellum of 8-month-old mice when compared to the 
C57/B6 control group. GFAP-IL6 mice treated with Longvida curcumin also showed a significant decrease in 
Iba-1+ microglia in the cerebellum of 8-month-old mice when compared to the untreated GFAP-IL6 mice. 
This supports the claim that Longvida curcumin has anti-inflammatory properties when fed to transgenic mice. 
Finally, Iba-1+ markers of Tenilsetam and Longvida curcumin were directly compared. Both testing 
cohorts had similar levels of Iba-1+ microglia in C57/B6 control groups, this indicates that the control groups 





2.1 Overview of neurodegenerative disease 
The term dementia encompasses a group of chronic neuropathological diseases that are characterised 
by a perpetual decline in multiple cognitive domains which constitute behavioral problems, memory 
impairment, loss of participation in social activities, loss of independence and loss of initiative(4). Dementia is 
placed under the category of major neurological disorders as it impairs everyday activities and cognitive 
function(5).  
Among the elderly population, dementia is the leading cause of disability and dependency with 35.6 
million people suffering from dementia worldwide in 2012, with approximately 7.7 million new cases reported 
annually(6). Reports estimate that dementia incidence will double every year, by the year 2040 there will be 
approximately 81 million cases of dementia worldwide(6). Among the most common forms of dementia is 
Alzheimer’s disease, it accounts for approximately 70% of all known sporadic, late-onset cases of dementia. 
Other forms of dementia include vascular dementia, dementia with Lewy bodies, mixed dementia, 
frontotemporal lobar degeneration, Parkinson’s disease, Creutzfeldt-Jakob disease, and normal pressure 
hydrocephalus(7). 
There is no simple, definitive test that exists to diagnose AD, rather, a physician with the help of a 
neurologist will employ a multi-step protocol to achieve a diagnosis, this may include: obtaining prior personal 
and family medical history, obtaining information about patients cognitive and motor changes from a close 
family member, conducting cognitive and physical tests along with blood tests and neuroimaging(7). Although 
significant improvements in clinical diagnosis have been made, effective treatments for AD are yet to be 





2.2 Origin of neuroinflammation and its effects on neurodegeneration 
The term ‘neuroinflammation’ can apply to CNS specific, inflammation-like glial responses that do 
not reproduce the signs of inflammation but cause neurodegeneration. Emerging evidence supports the idea 
that inflammation within the CNS plays a noticeable role in the pathogenesis of neurodegenerative diseases 
such as AD(10). Sustained neuroinflammation can lead to high levels of reactive oxygen and nitrogen species, 
oxidative stress and oxidated forms of lipids and proteins which result in neuronal, synaptic damage and 
neurodegeneration(11). Oxidative stress-related mechanisms contribute to a variety of neurodegenerative 
diseases such as Parkinson’s disease(12), amyotrophic lateral sclerosis(13), epilepsy(14) and AD(15). 
In chronic inflammatory conditions where neurodegeneration is common, low levels of cytokines, free 
radicals, reactive oxygen species (ROS) and toxic gene products in the brain gradually increase during ageing. 
This interferes with complex biochemical processes inhibiting bioenergetic reactions in the brain. As a result, 
oxidative affliction can catalyse additional ROS production from mitochondrial brain cells, most notably 
microglia as a consequence of amplified secretion of proinflammatory cytokines(11).  
Microglia embody the innate immune system and are therefore the first line of defence within the CNS. 
They constitute approximately 10% of the cells in the CNS(16), with each microglial cell constantly occupying 
and surveying a unique designated area(17, 18) to defend against pathogens and identify any damaged brain 
tissue(17, 19). Neurodegenerative diseases, including AD, Parkinson’s disease and chronic traumatic 
encephalopathy have common pathogenic factors including chronic microglial activation, meaning that when 
microglial cells are activated, they migrate toward and encompass any pathogenic, damaged or necrotic tissue 
or misfolded and aggregated proteins(20, 21) and subsequently remove cellular debris(22). 
Once microglia become immunostimulated as a consequence of neurodegenerative events, they release 
an array of pro-inflammatory mediators such as reactive oxygen and nitrogen species, prostaglandins, Tumour 




inflammatory factors listed can contribute to neuronal dysfunction and cell death leading to a detrimental self-
propagating cycle(23)  which is observed in brains suffering from AD during all stages of the disease(24).  
Astroglia have also been observed to transition from a basal, ramified state to a reactive state, exposing 
neurons to neurotoxins such as reactive oxygen species and pro-inflammatory cytokines(25). Genomic studies 
have also identified genes: CLU, CR 1 and TREM 2 as pro-inflammatory factors that increase the risk of 
developing AD(26). From the evidence discussed, it is believed that a self-perpetuating cycle of inflammatory 
neurotoxicity is a contributing factor to neurodegenerative diseases such as AD. 
2.3 Mouse models of neuroinflammation 
Transgenic modification technology is available for many organisms, including rats, mice, flies, fish, 
and worms. AD model work in invertebrates provides several advantages such as short life span of the 
organisms being tested and a high degree of experimental control of the organisms. However, invertebrates 
suffer a substantial disadvantage of being phylogenetically distant from mammals. Among vertebrates, mice 
are the most widely used species due to it being inexpensive to perform transgenic modifications due to the 
technology being well developed; also mice have a relatively short life span with short gestation periods and 
high litter birth rate(27). 
Advancements in gene-editing technology have seen an increase in genetic modifications in transgenic 
mice leading to various mouse models exhibiting increased levels of inflammatory factors leading to 
neurodegenerative diseases in the brain. Three noteworthy neuroinflammatory models have been developed 
and considered, lipopolysaccharide (LPS) induced, Il-1 and Il-6 transgenic animal models. 
LPS is a component of the bacterial wall in gram-negative bacteria, it has been observed to catalyse 
systemic peripheral inflammation, which ultimately also causes high-level brain inflammation. LPS acts as an 
endotoxin which evokes an inflammatory response by binding to toll-like receptors, this results in the process 




induced mechanisms on C57/B6 mice. Mice were intraperitoneally injected with a single 5mg/kg LPS dose 
and the inflammatory response was studied at several time points. 60 minutes post-injection, brain tissue 
analysis for TNF-𝛼 and mRNA showed peak levels of 7336% and 653% respectively when compared to saline 
injection controls. The temporal correlation between measured TNF-α transcript and protein levels taken from 
the liver and brain suggested that systemic LPS induced synthesis of TNF-α protein in the liver caused a 
multiple fold increase of protein levels in the brain. Immunohistochemical analysis of the hippocampus, 
cortex, and substantia nigra brain regions of the LPS treated animals found intense Iba-1 immunoreactive 
microglia with enlarged cytoplasm, cell body and irregular shape(28). 
Lee et al. (2008). Investigated the effects of LPS in peripheral neuroinflammation on inflammatory 
responses and cognitive performance in rats and mice. The animals were injected intraperitoneally with 
250µg/mg LPS before their learning and memory performance was assessed in passive avoidance and Morris 
water maze tests and compared to animals which received a saline injection control. They found that during 
the passive avoidance test, LPS treated mice displayed a significant reduction in step-through latency 
performance. The study also observed that LPS treated exhibited significantly longer escape times and 
distance when compared to control animals. This means the LPS treatment caused an adverse effect on the 
animals causing a decrease in cognitive performance and memory(29). 
IL-1 contributes an essential role of function in the CNS however, increased levels of IL-1 can 
contribute to hypothalamo-pituitary-adrenal axis and lead to sickness behaviour in animals(30). Two founder 
IL-1 lines, A/a and B/b were scrutinised two weeks after FIV-Cre injections via immunohistochemical 
analysis. IL-1βXAT B/b mice brain tissue was stained with Iba-1 antibody marker and found significant 
microglial activation, increased expression of MHC class II co-labeled for Iba-1 in perivascular and 
parenchymal sites. Additionally, IL-1βXAT B/b mice showed positive GFAP astroglial activation in dentate 
gyrus regions. IL-1βXAT A/a mice displayed minimal microglial activation and MHC class II expression in 




Ferrari et al. (2004), injected AdhIL-1β into Wistar rats and immunostained for polymorphonuclear 
neutrophils (PMN) after 2 days. The results showed a minimal difference in leukocyte presence in the blood 
vessels located at the injection site. Testing at 8 and 14 days after injection showed a widespread of neutrophils 
across the striatum, vasodilation of blood vessels filled with PMNs, however, no meningeal inflammation was 
found in parenchymal brain tissue. Immunohistochemical analysis of these animals have shown that 2 days 
after the AdhIL-1β, GSA positive microglia and ED-1 positive neutrophils recruited close to the injection site 
and GFAP positive astroglia were present in the striatum of that’s and was not present in the control group. 
ED1+ microglia exhibiting phagocytic activity was present throughout the whole striatum at 8 and 14 days 
post-injection. Additionally, GSA+ microglia expressing phagocytic and ramified morphology were present 
proximally and distally to the injection site. GFAP+ cells were observed to be resent throughout the entire 
striatum of the tested animals(32). 
Although transgenic mouse models are widely used for AD research, they do have some drawbacks, 
many models do not reproduce the whole spectrum of AD pathologies such as neuronal loss and chronic 
neuroinflammation. For example, neither Tg2576 nor PDAPP mice, display any neuronal loss despite 
expressing extensive amyloid deposition(33, 34). Another obstacle transgenic mouse models face is the 
expression of cytoskeletal pathology characteristics of AD(35). Ultimately, the transgenic mouse models 
mentioned above are engineered around the expression of mutant genes associated with AD pathogenesis in a 
relatively small subset of patients. Although these AD models generally exhibit early age onset, FAD cases 
seem to phenocopy pathological and clinical characteristics of sporadic cases relatively well, however, it is 
possible that the induced effects of the mutations are not present in sporadic AD(36) 
2.4 The GFAP-IL6 mouse model of chronic neuroinflammation 
The glial fibrillary acidic protein interleukin-6 (GFAP-IL6) mouse model, is used to model chronic 




transcriptional regulation of the GFAP promoter, this allows researchers to scrutinise cytokine signaling in 
the brain(37, 38). It does so by producing CNS targeted pro-inflammatory cytokine IL-6(37), IL-1β(39) and TNF-
α(40) levels are boosted as a result of the increased levels of IL-6, thus, triggering sustained chronic 
neuroinflammation. While the homozygous GFAP-IL6 mice have a life expectancy of fewer than 12 months, 
the hemizygous GFAP-IL6 mice live notably longer and begin to exhibit cognitive and motor deficits at 
approximately 12 months of age. It is important to note that this particular strain of GFAP-IL6 mice was 
created in 1993, however, cytokine suppressive anti-inflammatory drugs (CSAIDs) such as curcumin and 
Tenilsetam have not yet been therapeutically tested using this mouse model.  
The original construction of the GFAP-IL6 fusion gene and production of transgenic mice took place 
in 1993 under the collective work of Campbell, I.L et al., the methods are as follows. Firstly, a GFAP 
expression vector was used to target the expression of IL-6 to astrocytes. Previous studies showed that the use 
of this vector along with a similar one direct astrocyte-specific expression of 3-galactosidase and a1-
antichymo-trypsin (ACT) in transgenic mice. Full length complementary deoxyribonucleic acid (cDNA) for 
murine IL-6 was altered by inserting a 196-bp simian virus 40 (SV40) late region fragment into the 3’ 
untranslated region, providing a polyadenylation signal. To improve in vivo expression efficiency, the IL-6 
cDNA was inserted into unique Sal I restriction site of murine GFAP gene after the mutation of both ATG 
codons between the transcriptional start site and the Sal I site in the exon 1 to TTG codons by recombinant 
PCR primer modification and inserting an SV40 late-gene splice 5’ to the IL-6 cDNA. The GFAP fusion genes 
regardless of whether GFAP-lacZ was present were microinjected into fertilized eggs of (C57BL/6J x SJL) 
F1 hybrid mice. Transgenic offspring were identified by slot-blot analysis of tail deoxyribonucleic acid (DNA) 
with 32P labeled SV40 late region fragment(41). 
The inbred C57/BL6 strain is among the most commonly used mouse strains for the production and 
analysis of transgenic and knockout animal models. Since the creation of the C57/BL6 strain in the Jackson 




genetically identical, behavioural differences have also been documented between the two strains(43-45). The 
genetic divergence of the inbred strain can be attributed to single nucleotide polymorphisms (SNPs) and 
polygenic mutational variability constantly arising in the inbred populations as new sources of genetic 
polymorphisms(46). The involuntary polygenic mutations catalysing genetic divergence can also be called 
‘genetic drift’, and it has been observed to occur in the C57/BL6J strain(47, 48), with SNPs and polygenic 
mutations accumulating up to a significant percentage of 4.5% phenotypic variance(49). Genetic drift within 
the laboratory setting is expected to increase genetic differentiation between two strains over time. This is 
especially true when artificial constriction of a population occurs such as the establishment and/or relocation 
of a colony(50). 
2.5 Anti-inflammatory compounds and their applications 
Inflammatory conditions in the CNS are mainly treated using non-steroidal anti-inflammatory drugs 
(NSAIDs) which specifically inhibit cyclooxygenases (COXs), however, they do not affect the creation of 
pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 or nitric oxide produced by inducible nitric oxide 
synthase (iNOS)(51), therefore having a narrow range of anti-inflammatory efficacy. Drugs with a broader 
range of anti-inflammatory effectiveness, such as CSAIDs are a good alternative to NSAIDs, due to CSAIDs 
ability to inhibit a large proportion of pro-inflammatory cytokines by targeting the NF-κB and AP1 signaling 
pathways(52-54). Two potential candidates, Longvida curcumin and Tenilsetam will be used in this study due 
to their ability to penetrate the blood-brain barrier (BBB) and gain access into the CNS(55), this, in turn, allows 
the CSAIDs to trigger anti-inflammatory effects in the brain. 
Currently, there are no pharmacological treatments available to effectively prevent or reverse neuronal 
and synaptic degradation induced via the progression of AD, ultimately making the disease fatal(7). CSAIDs 





The nootropic drug (±)-3-(2-thienyl)-2-piperazinone (CAS 997, Tenilsetam), exhibits antiamnesic, 
antihypoxidotic and antidementia properties, which are beneficial for AD patients(38). Ihl et al. demonstrated 
a significant increase in AD patient performance after being administered 150mg/day for 3 months in the 
Favourability Judgement Task (FJT)(56). In another study, 15 elderly patients of both sexes aged between 58-
77 years showed Tenilsetam to have dose-dependent effects on the N1-P2 and N2-P300 amplitudes of the 
event-related potentials (ERPs) when tested via the Viennese Psychophysiological Test-System (VPTS)(57).  
It is believed that Tenilsetam acts under several mechanisms, the first of which inhibits the formation 
of proteins and protein crosslink by advanced glycation endproducts (AGEs)(58-60). It is thought that decreasing 
the formation of AGE will lower total AGE levels thus reducing pro-inflammatory activation of AGE, receptor 
of advanced glycation endproduct (RAGE)(61, 62). Secondly, by scavenging carbonyl and dicarbonyl 
compounds (e.g. methylglyoxal)(63).  
Tenilsetam was clinically assessed for the anti-inflammatory properties it possesses, particularly, its 
ability to affect delayed-type hypersensitivity (DTH) reactions. Reactions involving DHT are cell-mediated 
antigen-specific immune responses that may be harmful to the host such as autoimmunity and allergic 
dermatitis. A typical immune response of DTH is characterised by localised swelling and the presence of 
monocytes/macrophages and lymphocytes in the dermis and epidermis. In a septic shock and inflammation 
animal model that was designed to emulate septic shock in humans, bolus injections of sublethal or lethal 
doses of lipopolysaccharide (LPS) resulted in an increase in TNF-α levels in the serum of mammals. The LPS 
administered into the treated mice increased TNF-α levels found in serum up to approximately 1.8µg/ml. 





Various data sources had suggested that Tenilsetam is a fitting candidate to help reduce the detrimental 
effects of chronic neuroinflammation and that its anti-inflammatory properties may be validated in the GFAP-
IL6 mouse model(38, 65). In the current study, Tenilsetam was tested on GFAP-IL6 mice in a short and a long-
term study (5 and 15 months, respectively). The results showed a decrease in total Iba-1+ microglia in the 
cerebellum and hippocampus, prevented cerebellar volume loss at 8 months of age, decreased microglial 
density in GFAP-IL6 mice to similar levels after 5 and 15 months of feeding and significantly decreased TNF-
α levels to a similar level of WT mice after 15 months of feeding. This was the first study to quantify the anti-
inflammatory effects of Tenilsetam in the GFAP-IL6 mouse model(64). 
2.5.2 Curcumin 
Curcumin (1E,6E)-1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is the primary 
curcuminoid of Curcuma longa Linn. It is effective via large cytokine suppressive anti-inflammatory action, 
downregulating the expression of cyclooxygenase-2 (COX-2), TNF-α, iNOS, IL-1, -2, -6, -8 and -12, 
monocyte chemo-attractant protein (MCP) and migration inhibitory protein(66-69). Curcumin has been shown 
to work through several different mechanisms, in vitro studies reveal that curcumin blocks cytokine gene 
expression by inhibiting the activation of transcript factors nuclear factor kappa B (NF-κ B) and activating 
protein-1 (AP-1) in activated macrophages and monocytes(70, 71). Curcumin also inhibits IL-6 mediated 
signalling by disrupting IL-6 induced by STAT 3 phosphorylation and STAT 3 nuclear translocation(72), while 
also interfering with microglial activation(73).  
Commercially available versions of curcumin such as “Longvida” (VS Corp) are highly bioavailable 
via encapsulation in liposomes allowing it to achieve µM concentrations in the brain(74, 75). For example, 
certain curcumin compounds reach concentrations up to 3 µM, tetrahydrocurcumin (TC) can reach 
concentrations up to 6 µM, EC50 values of 1.2 and 0.701 µM for curcumin and TC were respectively 




Lim et al. tested the anti-oxidative and anti-inflammatory properties of curcumin on 10-month-old 
Tg2576 transgenic mice fed a curcumin-based diet (160 ppm) for 6 months. The results revealed a significant 
decrease in oxidised protein levels, along with IL-1β, plaque burden and soluble and insoluble Aβ(76). Further 
studies by Yang et al. evaluated the efficacy of a curcumin-based diet (500 ppm) on 17-month-old Tg2576 
transgenic mice for 6 months. The study found that curcumin reduced soluble amyloid levels and plaque 
burden in mice with advanced amyloid accumulation(77). Furthermore, curcumin's ability to adjust cholinergic 
neurotransmission and, therefore, improve memory impairment and cognitive deficiencies in aged rats has 
also been demonstrated(78). 
 
3.  Hypothesis and aims for this research project 
 
3.1 Hypothesis 
It is hypothesised that both Tenilsetam and Longvida curcumin will reduce the total number of 
microglial cells in the cerebellum and hippocampus of GFAP-IL6 mice after short term and long term feeding 
and consequently reduce neuroinflammation.  
3.2 Aims 
This thesis aims to:  
• Identify the effects of Tenilsetam on total microglial numbers in the cerebellum and hippocampus of 
8 and 18 month old GFAP-IL6 mice after 5 and 15 months treatment. 
• Identify the effects of Longvida curcumin on total microglial numbers in the cerebellum of 8-month-
old GFAP-IL6 mice after 5 months treatment. 
• Directly compare the efficacy of Tenilsetam and Longvida curcumin on the total Iba-1+ microglial 




4.  Methods  
 
4.1 Preparation of rodent chow  
 
Longvida is optimized curcumin with high bioavailability properties. It is synthesized by technology 
developed Verdure Sciences Co and UCLA scientists in the USA using curcumin-lipid micelles to obtain solid 
lipid nanoparticles. Mouse food pellets were produced by Specialty Feeds in Australia in accordance with 
NRC guidelines for mouse and rat diet ration. It was composed of the following ingredients: wheat, barley, 
lupins, soya meal, fish meal, mixed vegetable oils, canola oil, salt, calcium carbonate, dicalcium phosphate, 
magnesium oxide, vitamins, and trace mineral premix. The drug mixed food also contained 500 parts per 
million (ppm) or 500 mg/kg dose of Longvida curcumin. The pellets consist of a standard irradiated mouse 
fixed formulation diet for laboratory rodents fortified with vitamins and minerals to meet the requirements of 
breeding animals (protein 20.00% total fat, 4.80% crude fiber 4.80%, digestible energy 14.0 MJ/ Kg). 
The calculated average daily dosing of mice with Longvida curcumin from their measured daily food 
consumption amount and measured bodyweights were 51-60 mg per kg body weight per day. Mice were added 
to each of the four feeding groups of the study by consecutive cohorts’ design. All animal research procedures 
were performed according to Animal Care and Ethics Committee guidelines and approval (Animal Research 
Authority #A10057) at Western Sydney University. Overall health and functional condition of mice were 
monitored weekly (see below for details) and their bodyweights were recorded in every second week.  
 
The Tenilsetam containing experimental diet pellets were formulated by Specialty Feeds Pty Ltd., 
Western Australia. The pellets consist of a standard irradiated rat and mouse fixed formulation diet for 
laboratory rodents fortified with vitamins and minerals to meet the requirements of breeding animals (protein 
20.00% total fat, 4.80% crude fiber 4.80%, digestible energy 14.0 MJ/ Kg), milled with Tenilsetam at a 




randomly assigned to 3 groups: 1. C57BL/6 mice fed with control food pellets (n = 6–10); 2. GFAP-IL6 mice 
fed with food pellets containing Tenilsetam (n = 6–10); 3. GFAP-IL6 mice fed with control food pellets (n = 
6–10). Mice were housed in groups of no more than 3 per cage to monitor physical conditions on a weekly 
basis. Bodyweight of the animals on the diet was measured 2 months after introducing the Tenilsetam 
containing diet, to check if it has affected their food intake and body weight. Cage food trays were weighed 
before and after supply was refreshed to ensure mice were consuming the food. At the age of 8 months, 3–5 
mice in each group were perfused for histology. The remaining mice were fed until they were 18 months old 




 3 month old GFAP-IL6 and pre-existing heterozygous C57/B6 lineage (mixed gender) mice were 
treated for 5 and 15 months and sacrificed at the age of 8 and 18 months for this study. The mice were bred in 
the animal house of the School of Medicine, Western Sydney University. They were housed in a temperature-
controlled environment, with a normal 12:12 hour light-dark cycle and free access to food and water. All 
procedures were approved by Western Sydney University Animal Care and Ethics Committee and followed 
the Guidelines to Promote the Wellbeing of Animals used for Scientific Purposes as laid out by the National 
Health and Medical Research Council of Australia. Control mice were fed with normal mouse chow. 
Firstly, the mice in the Tenilsetam 8 month cerebellum and hippocampal cohort were assigned to 3 
groups after weaning: 1. C57/B6 control mice fed with standard food pellets (mentioned above) (n = 4); 2. 
GFAP-IL6 control mice fed with standard food pellets (n = 5); 3. GFAP-IL6 mice fed with Tenilsetam 
enriched food pellets (n = 4). The mice were left to age for 3 months before the Tenilsetam enriched diet was 




Secondly, the mice in the Tenilsetam 18 month cerebellum and hippocampal cohort were assigned to 
3 groups after weaning: 1. C57/B6 control mice fed with standard food pellets (n = 3); 2. GFAP-IL6 control 
mice fed with standard food pellets (n = 3); 3. GFAP-IL6 mice fed with Tenilsetam enriched food pellets (n 
= 3). The mice were left to age for 3 months before the Tenilsetam enriched diet was introduced and were fed 
for 15 months before being sacrificed. 
Finally, after weaning the Longvida curcumin 8-month cerebellum cohort were assigned to 4 groups: 
1. C57/B6 control mice fed with standard food pellets (n = 4); 2. C57/B6 fed with Longvida curcumin enriched 
food pellets (n = 6); 3. GFAP-IL6 mice fed with standard food pellets (n = 7); 4. GFAP-IL6 mice fed with 
Longvida enriched food pellets (n = 4). The mice were left to age for 3 months before the Longvida curcumin 
enriched diet was introduced and were fed for 5 months before being sacrificed. 
Mice were housed in groups of no more than 3 per cage and no less than 2 per cage to monitor physical 
conditions on a weekly basis. The mice and cage food trays were weighed before and after supply to ensure 
mice were consuming the food. At the age of 8 and18 months, the mice within each group were perfused for 
histological analysis or fresh brain tissue samples were extracted and snap-frozen in liquid nitrogen for future 
genetic experimentation. 
4.3 Histology and tissue processing 
At 8 and 18 months of age, the mice were anaesthetised with isoflurane and transcardial perfusion was 
performed. Mice were flushed with 30 ml of 0.9% normal saline using a peristaltic pump, followed by 60 ml 
of 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were removed and post-fixed in 4% 
paraformaldehyde for at least 2 h at 4°C, and then transferred to 30% sucrose (in 0.1 M PB solution) for 
cryoprotection. After the brains sank to the bottom of the container, they were cut into 40 µm thick coronal 
sections using a Leica CM 1950 cryostat. Every 8th section from the brain was used for immunohistochemistry 




otherwise. For Iba-1 staining, sections were washed and treated with 1% H2O2 before being transferred to 2% 
goat serum to block non-specific antigen-binding sites for 2 h. Then they were incubated in the primary rabbit-
anti Iba-1 antibody (1:500, Wako, # 019–19741) solution for two days at 4°C and subsequently in the 
secondary antibody (biotinylated goat anti-rabbit IgG; Life Technologies, #656140, 1:200) for 2 h. The 
sections were then washed and transferred to the ABC solution (1:250, Vector Laboratories, # PK-6100) for 
2 h. Sections were then incubated in the developer solution containing 0.4 mg/ml DAB and 0.0006% hydrogen 
peroxide until an optimal colour developed. At the end of the procedure, the sections were mounted and 
dehydrated in increasing concentrations of ethanol ranging from 75-100% before being soaked in xylene and 
cover-slipped. For fluorescent staining against TSPO, sections were incubated in the primary antibody (rabbit-
anti-TSPO, 1:500, Merck, #ABC139; rabbit-anti-GFAP, 1:500, Dako, # Z0334) solutions for overnight at 
room temperature and subsequently in the secondary antibody solutions (Alexa 594-goat-anti-rabbit IgG-
#A11012 and Alexa 488goat-anti-rabbit IgG-#A11008, 1:250; Life Technologies) for 2 h at room temperature. 
Sections were mounted after washing and coverslipped with a fluorescent mounting medium (Vector 
Laboratories, #H1400). 
4.4 Stereological counting 
To estimate the absolute microglial cell number in the cerebellum and hippocampus, Iba-1 and TSPO 
sections were counted using the optical fractionator probe(64, 79). The contour of the cerebellum was first drawn 
under a 2.5× objective. For Iba-1 staining, the size of the counting frame for the cerebellum was 100 × 100 
μm for C57BL/6 and Tenilsetam treated GFAP-IL6 mice, 50 × 50 μm for GFAP-IL6 mice on control food 
pellets. The counting grid was 1000 × 1000 μm for C57/B6 and Tenilsetam treated GFAP-IL6 mice, 1000 × 
1500 μm for GFAP-IL6 mice on control food pellets. The size of the counting frame for the hippocampus was 
100 × 100 μm, and the counting grid 1000 × 1000 μm for all groups. For TSPO staining, the size of the 
counting frame was 50 × 50 μm for the cerebellum and 100 × 100 μm for the hippocampus for GFAP-IL6 




cerebellum and 1000 × 1500 μm for the hippocampus. Due to the small number of TSPO positive cells in the 
cerebellum of C57/B6 mice, the counting frame was increased to 150 × 150 μm, and the grid size was 
decreased to 500 × 500 μm. However, the hippocampus of C57/B6 mice only had less than 10 cells after 
examining over 200 sampling sites. Therefore, its count of TSPO positive cells could not be stereologically 
estimated and was not included in the statistical analysis. The guard zone was set to 1 μm at the top and the 
bottom of the sections. These different parameters ensured that 3–5 cells were present in each counting frame 
and the total number of cells was not overestimated due to too many cells in each counting frame or 
underestimated due to few cells in each counting frame(80). Iba-1 and TSPO positive cells were plotted on the 
screen using a marker as the focus moved from the top to the bottom of the sections using a 63× oil objective. 
This had led to the Gunderson coefficient error of less than 0.1 in all cases (m = 1). For volume estimation, 
the area of interest (the cerebellum) was traced in sections at 2.5× magnification and the cerebellar volume 
was estimated using the Cavalieri method. 
The estimation of the absolute microglial cell number in the cerebellum of the Longvida curcumin 
mice were counted on Iba-1 stained sections using the optical fractionator probe(64, 79). The contours of the 
cerebellum were first drawn under a 2.5× objective. For Iba-1 staining, the size of the counting frame for the 
cerebellum was 100 × 100 µm and a counting grid of 1000 × 1000 µm was used for all control and variable 
groups. The guard zone was set to 1 µm at the top and the bottom of the sections. These different parameters 
ensured that 3–5 cells were present in each counting frame and the total number of cells was not overestimated 
due to too many cells in each counting frame or underestimated due to few cells in each counting frame(80). 
Iba-1 positive cells were plotted on the screen using a marker as the focus moved from the top to the bottom 
of the sections using a 63× oil objective. This had led to the Gunderson coefficient error equal to or less than 
0.1 in all cases (m =1). For volume estimation, the area of interest (the cerebellum) was traced in sections at 




4.5 Data analysis 
For all our analyses, we used one-way ANOVAs in GraphPad version 8. Two-way ANOVA was used 
to analyse the statistical differences between Tenilsetam and Longvida curcumin testing groups, and for every 
other statistical analysis we used one-way ANOVA, with Bonferroni corrected multiple comparisons. 
Differences were regarded as statistically significant when p < .05 indicates the value of the F-test, the degrees 
of freedom of the numerator and denominator and the significance, respectively. Results were presented as 
mean ± SEM. 
Erika Gyengesi, Huazheng Liang, Christopher Millington, Sandra Sonego, Daniel Sirijovski, Dhanushka 
Gunawardena, Karthik Dhananjayan, Madhuri Venigalla, Garry Niedermayer, Gerald Münch. Investigation 
into the effects of Tenilsetam in the Markers of Neuroinflammation in GFAP-IL6 Mice. Pharm Res. 2018 
Jan 5;35(1):22. DOI: 10.1007/s11095-017-2326-9. 
In the above publication, I, Daniel Sirijovski contributed to the following: All stereological 
measurements including cerebellar and hippocampal volume estimations, total Iba1+ microglia and TSPO+ 
microglia counts in the cerebellum and hippocampal regions along with cerebellar and hippocampal volume. 







5.1 Number of TSPO+ microglia in the cerebellum of 8-month-old Tenilsetam fed mice 
The purpose of this test was to elucidate whether Tenilsetam is effective at reducing the total number 
of TSPO+ microglia in the cerebellum of 8-month-old mice. Statistical significance was found between 
C57/B6 control mice (209896 ± 99389) and GFAP-IL6 control group (617371 ± 28443) (p < 0.05); and the 
C57/B6 control mice (209896 ± 99389) and the GFAP-IL6 Tenilsetam fed mice (960670 ±204365) (p < 0.01). 
No statistical significance was present between the GFAP-IL6 control group (617371 ± 28443) and the GFAP-























Figure 1. Comparison between the absolute number of TSPO+ microglia in the cerebellum C57/B6 control mice, GFAP-IL6 control mice and 
GFAP-IL6 mice fed with Tenilsetam at 8 months of age, respectively. (a-c). Photographs of the cerebellum of C57/B6 control mice, GFAP-IL6 
control mice and GFAP-IL6 mice fed with Tenilsetam at 8 months of age, respectively. (d). Comparison between the absolute number of TSPO+ 
microglia in the cerebellum C57/B6 control mice, GFAP-IL6 control mice and GFAP-IL6 mice fed with Tenilsetam at 8 months of age, 
respectively Note: * indicates p < 0.05 and ** indicates p < 0.01. 
 
5.2 Number of TSPO+ microglia in the cerebellum of 18-month-old Tenilsetam fed mice 
 The goal of this test is to evaluate the anti-inflammatory properties of Tenilsetam by statistically 
comparing total TSPO+ microglia in the cerebellum of 18-month-old mice. Statistical significance was found 
between C57/B6 control mice (232575 ± 75744) and GFAP-IL6 control group (718582 ± 60219) (p < 0.0001); 
and the C57/B6 control mice (232575 ± 75744) and the GFAP-IL6 Tenilsetam fed mice (686580 ± 89593) (p 
< 0.0001). No statistical significance was present between the GFAP-IL6 control group (718582 ± 60219) and 





















Figure 2. Comparison between the absolute number of TSPO+ microglia in the cerebellum C57/B6 control mice, GFAP-IL6 control mice and 
GFAP-IL6 mice fed with Tenilsetam at 18 months of age, respectively. (a-c). Photographs of the cerebellum of C57/B6 control mice, GFAP-IL6 
control mice and GFAP-IL6 mice fed with Tenilsetam at 18 months of age, respectively. (d). Comparison between the absolute number of 
TSPO+ microglia in the cerebellum C57/B6 control mice, GFAP-IL6 control mice and GFAP-IL6 mice fed with Tenilsetam at 18 months of age, 
respectively Note:  **** indicates p < 0.0001. 
 
5.3 Comparison between Tenilsetam fed mice at the 8 and 18-month time point for TSPO+ 
microglia 
 A direct comparison between the two age groups was conducted to elucidate whether Tenilsetam will 
reduce TSPO+ microglial numbers after extended periods of feeding. The results yielded no statistically 
significant results of interest. A side by side comparison can be seen in figure 3. 
































Fig 3. Side by side visual comparison of total TSPO+ microglia in the cerebellum of 8 and 18-month-old mice. 
5.4 Number of TSPO+ microglia in the hippocampus of 8-month-old Tenilsetam fed mice 
Tenilsetam’s ability to reduce chronic neuroinflammation in the hippocampus of 8-month-old mice 
was scrutinised via stereological counting of TSPO+ microglia. A significant difference was observed between 
C57/B6 (181560 ± 75995) and GFAP-IL6 control (239726 ± 97674) (p < 0.001) along with C57/B6 (181560 




difference observed between the GFAP-IL6 control (239726 ± 97674) and GFAP-IL6 Tenilsetam fed mice 














Figure 4. Stereological counting of TSPO+ cells in the hippocampus of C57/B6 control mice, GFAP-IL6 mice fed control pellets and GFAP-IL6 
mice fed Tenilsetam pellets respectively at 8 months of age. (a-c). Photographs of the hippocampus of C57/B6 control mice, GFAP-IL6 control 
mice and GFAP-IL6 mice fed with Tenilsetam at 8 months of age, respectively. (d). Comparison between the absolute number of TSPO+ microglia 
in the cerebellum C57/B6 control mice, GFAP-IL6 control mice and GFAP-IL6 mice fed with Tenilsetam at 8 months of age, respectively * 
indicates p < 0.05. NOTE: *** indicates p < 0.001. 
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5.5 Number of TSPO+ microglia in the hippocampus of 18-month-old Tenilsetam fed mice 
At the 18 month time point, a significant difference was observed between the C57/B6 (236807 ± 
79549) and GFAP-IL6 control mice (472833 ± 61843) (P < 0.05), however, there were no significant changes 
observed between C57/B6 (236807 ± 79549) and GFAP-IL6 Tenilsetam fed mice (420326 ± 28707) (p > 
0.999) and GFAP-IL6 control (472833 ± 61843) and the GFAP-IL6 Tenilsetam fed mice (420326 ± 28707) 








































































































Figure 5. Stereological counting of TSPO+ cells in the hippocampus of C57/B6 control mice, GFAP-IL6 mice fed control pellets and GFAP-IL6 
mice fed Tenilsetam pellets respectively at 18 months of age. (a-c). Photographs of the hippocampus of C57/B6 control mice, GFAP-IL6 control 
mice and GFAP-IL6 mice fed with Tenilsetam at 18 months of age, respectively. (d). Comparison between the absolute number of TSPO+ microglia 
in the cerebellum C57/B6 control mice, GFAP-IL6 control mice and GFAP-IL6 mice fed with Tenilsetam at 18 months of age, respectively. 
NOTE: * indicates p < 0.05. 
 
5.6 Hippocampal volume of 8-month-old Tenilsetam fed mice 
Hippocampal volume was stereologically measured to help elucidate whether chronic neuroinflammation 
leads to cell death. In the hippocampus of Tenilsetam fed mice, no statistical difference was observed between 















































8 month old mice Hippocampal volume
 
Fig. 6. Hippocampal volume of 8-month-old C57/B6, GFAP-IL6, and GFAP-IL6 Tenilsetam fed mice respectively. 
5.7 Hippocampal volume of 18-month-old Tenilsetam fed mice 
Stereological measurement of hippocampal volume was used to compare and evaluate whether chronic 
neuroinflammation causes neuronal cell death. In the 18 month old Tenilsetam treated mice, statistical 




IL6 control group (18.3 ± 1.5 mm3) (p < 0.01) and groups C57/B6 control mice (22.2 ± 2.4 mm3) and GFAP-
IL6 Tenilsetam treated mice (17.8 ± 0.9) (p < 0.01). (Fig.7) No differences were found between GFAP-IL6 


















































Fig. 7. Hippocampal volume of 18-month-old C57/B6, GFAP-IL6, and GFAP-IL6 Tenilsetam fed mice respectively. Note  ** indicates p < 0.01 
5.8 Number of Iba-1+ Microglia in the cerebellum of 8-month-old Tenilsetam fed mice 
The anti-inflammatory properties of Tenilsetam was evaluated via stereological counting of Iba-1+ 
microglia in the cerebellum at the 8 month time point, statistical significance was found between C57/B6 wild 
type control mice (271067 ± 53388) and GFAP-IL6 control group (1610357 ± 189736) (p < 0.0001); C57/B6 
wild type control mice (271067 ± 53388) and GFAP-IL6 Tenilsetam fed (920646 ± 55422) (p < 0.0001); and 
GFAP-IL6 control group (1610357 ± 189736) and GFAP-IL6 Tenilsetam fed (920646 ± 55422) (p < 0.0001). 


















Figure 8. Stereological counting of Iba-1+ cells in the cerebellum of C57/B6 control mice, GFAP-IL6 control mice and GFAP-IL6 mice fed with 
Tenilsetam food pellets respectively at 8 months of age. (a-c). Photographs of the cerebellum of C57/B6 control mice, GFAP-IL6 control mice 
and GFAP-IL6 mice fed with Tenilsetam at 8 months of age, respectively. (d). Comparison between the absolute number of Iba-1+ microglia in 
the cerebellum C57/B6 control mice, GFAP-IL6 control mice and GFAP-IL6 mice fed with Tenilsetam at 8 months of age, respectively. Note: 
**** indicates p < 0.0001. 
 
5.9 Cerebellar volume of 8-month-old Tenilsetam fed mice 
Cerebellar volume was measured to evaluate whether chronic neuroinflammation affects cell death in 
































































and the GFAP-IL6 Tenilsetam fed mice (31.4 ± 2.1) (p < 0.001); and GFAP-IL6 control group fed normal 
food pellets (23.8 ± 2.1 mm3) and the GFAP-IL6 Tenilsetam fed mice (31.4 ± 2.1 mm3) (p < 0.01). There was 












Figure 9. Cerebellar volume of 8-month-old C57/B6, GFAP-IL6, and GFAP-IL6 Tenilsetam fed mice. ** indicates p < 0.01 and *** indicates p 
< 0.001 
 
5.10 Cerebellar volume of 18-month-old Tenilsetam fed mice 
 Cerebellar volume was measured to evaluate whether chronic neuroinflammation affects cell death in 
the 18 month time group, a significant difference was found between the C57/B6 control group (37.6 ± 3.1 
mm3) and the GFAP-IL6 control group (29.6 ± 1.8 mm3) (p < 0.05). No other statistical significance was 
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Figure 10. Cerebellar volume of 18-month-old C57/B6, GFAP-IL6, and GFAP-IL6 Tenilsetam fed mice. Note: * indicates p < 0.05 
 
5.11 Comparison of cerebellar volume between 8 and 18-month-old mice 
 A comparison of cerebellar volume in 8 and 18-month-old mice treated with Tenilsetam. No statistical 
significance was observed between multiple comparisons of age groups. (Fig. 11) 





































5.12 Number of Iba-1+ microglia in the cerebellum of 8-month-old Longvida curcumin fed 
mice 
The anti-inflammatory properties of Longvda curcumin was stereologically measured via Iba-1+ 
microglia in the cerebellum at the 8 month time point, statistical significance was found between GFAP-IL6 
Longvida curcumin fed (318438 ± 32895) and C57/B6 control group (190226 ± 35763) (p < 0.5); GFAP-IL6 
control (459637 ± 119916) and C57/B6 control (190226 ± 35763) (p < 0.001) and GFAP-IL6 control group 
(459637 ± 119916) and GFAP-IL6 Longvida curcumin fed (318437 ± 32895) (p < 0.001). There were no other 



















Figure 12. Stereological counting of Iba-1+ cells in the cerebellum of GFAP-IL6 mice fed with Longvida curcumin food pellets, C57/B6 mice 
control mice and GFAP-IL6 control mice respectively at 8 months of age. (a-c). Photographs of the cerebellum of GFAP-IL6 mice fed with food 
pellets containing Longvida curcumin, C57/B6 control mice and GFAP-IL6 mice fed with control food pellets at 8 months. (d). Comparison 
between the absolute number of microglia in the cerebellum of GFAP-IL6 mice fed with food pellets containing Longvida curcumin, C57/B6 
control mice and GFAP-IL6 mice fed with control food pellets at 8 months respectively. * indicates p < 0.05, *** indicates p < 0.001. 
 
5.13 Cerebellar volume in 8-month-old Longvida curcumin fed mice 
Cerebellar volume was used to estimate cell death due to chronic neuroinflammation in 8-month-old 
Longvida curcumin fed mice. There were no significant differences observed between any testing group in 
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Figure 13. Cerebellar volume of 8-month-old C57/B6, GFAP-IL6, and GFAP-IL6 Longvida curcumin fed mice. 
 
5.14 Comparison between the efficacy of Tenilsetam and Longvida curcumin in reducing 
Iba-1+ microglia in the cerebellum of 8-month-old mice 
The efficacy of Tenilsetam and Longvida curcumin were directly compared by comparing the total 
number of Iba-1+ microglia in the cerebellum of 8-month-old mice. C57/B6 and GFAP-IL6 mice were treated 
with Tenilsetam and Longvida curcumin until 8 months of age, no statistical significance was observed 




± 35763) (p > 0.999) (Fig. 14a). Statistical significances were observed between Tenilsetam GFAP-IL6 control 
(1610357 ± 189736) and Longvida curcumin GFAP-IL6 control (459637 ± 119916) (p < 0.0001) (Fig. 14b); 
and Tenilsetam fed GFAP-IL6 (920646 ± 55422) and Longvida curcumin fed GFAP-IL6 (223213 ± 21213) 









Fig 14. (a) Stereological counting comparing Iba-1+ cells in the cerebellum of C57/B6 control mice from the Tenilsetam and Longvida curcumin 
testing group respectively at 8 months of age. (b) Stereological counting comparing Iba-1+ cells in the cerebellum of GFAP-IL6 control mice 
from the Tenilsetam and Longvida curcumin testing group respectively at 8 months of age. (c) Stereological counting comparing Iba-1+ cells in 






















































































































































Fig 15. Stereological counting comparing Iba-1+ cells in the cerebellum of C57/B6 control mice, GFAP-IL6 control mice, and GFAP-IL6 mice 
fed Tenilsetam and Longvida curcumin pellets respectively at 8 months of age. 
 
5.15 Comparing cerebellar volume between 8-month-old Tenilsetam and Longvida curcumin 
treated mice 
Cerebellar volume was measured to evaluate the effects of chronic neuro-inflammation on neuronal 
cell death. There were no statistically significant differences between any control or treatment groups when 
































Figure 16. Cerebellar volume of 8-month-old C57/B6, GFAP-IL6 and GFAP-IL6 mice treated with Tenilsetam and Longvida 
curcumin respectively. 
 
6.  Discussion 
Increased microglial numbers during periods of chronic neuroinflammation have been linked to early 
onset of neurodegenerative diseases, AD included. Currently, there are limited therapeutics available to target 
a range of inflammatory factors such as cytokines, iNOS and TNF-α and COX-2 to disrupt microglial 
activation. Evaluating the efficacy of available CSAID products such as Tenilsetam and Longvida curcumin 




This research project focused on independently identifying the efficacy of CSAIDs Longvida curcumin 
and Tenilsetam in reducing Iba-1+ and TSPO+ microglial numbers in the cerebellum of 8 and 18-month old 
GFAP-IL6 mice and also the efficacy of Tenilsetam and Longvida curcumin in reducing TSPO+ microglial 
markers in the hippocampus of 8 and 18-month old GFAP-IL6 mice. This project also investigated the effects 
of Tenilsetam on cerebellar and hippocampal volume in 8 and 18-month old GFAP-IL 6 and the effects of 
Longvida curcumin on cerebellar volume in 8-month-old GFAP-IL6 mice. This was followed by a subsequent 
comparison between the efficacies of Longvida curcumin and Tenilsetam in reducing total Iba-1+ microglial 
numbers in the cerebellum of 8-month-old GFAP-IL6 mice and Cerebellar volume in 8-month-old GFAP-IL6 
mice. 
TSPO is expressed in both macrophages and a portion of microglia in the brain(81). In the cerebellum 
of Tenilsetam fed mice, a statistically significant difference in TSPO+ microglia were observed between 
C57/B6 control mice and GFAP-IL6 control mice along with C57/B6 and GFAP-IL6 Tenilsetam treated mice 
at both 8 months (Fig. 1) and 18 months (Fig. 2) old age groups. No statistical significance was observed 
between the GFAP-IL6 control group and GFAP-IL6 treated groups at both age groups. This suggests that 
Tenilsetam had no effect on reducing the total TSPO+ microglial numbers in the cerebellum at either 8 or 18-
month-old mice. (Fig. 3) 
The effects of Tenlsetam on TSPO+ microglia in the hippocampus of 8 and 18-month-old mice were 
stereologically counted. A statistical significance was seen between the C57/B6 and GFAP-IL6 control mice 
along with the GFAP-IL6 control mice and GFAP-IL6 Tenilsetam treated mice in the 8 month age group (Fig. 
4). No statistical significance was seen between C57/B6 and GFAP-IL6 Tenilsetam treated group. This 
suggests that Tenilsetam treatment has a significant effect on reducing TSPO+ microglial markers and 
therefore chronic neuroinflammation in the hippocampus of 8-month-old GFAP-IL6 mice. After 18 months, 




this suggests that long term treatment of Tenilsetam does not decrease the total number of TSPO+ microglia 
in the hippocampus of chronically neuroinflamed mice. 
Alongside hippocampal inflammation, hippocampal volume was measured at 8 and 18-month time 
points. There was no significant difference between any control or variable group in the 8-month cohort (Fig. 
6). This implies that chronic neuroinflammation has no effect on hippocampal volume at 8 months of age and 
that Tenilsetam treatment has no significant effects on hippocampal volume at 8 months of age. After 18 
months, a statistically significant decrease was observed between both GFAP-IL6 groups when compared to 
C57/B6 control (Fig. 7). This implies that long term chronic neuroinflammation can contribute to hippocampal 
atrophy, however, there was no significant difference between GFAP-IL6 control and GFAP-IL6 Tenilsetam 
treated mice which suggests that long term Tenilsetam treatment has no observable effect on hippocampal 
volume. 
In the case of the 8-month-old Tenilsetam group, a statistical significance in Iba-1+ microglia in the 
cerebellum was found between all groups. Firstly, the GFAP-IL6 control group exhibited a significantly higher 
microglial population in the cerebellum than the C57/B6 control group (Fig. 8d), this indicates that the GFAP-
IL6 mice are experiencing chronic neuroinflammation. Secondly, and most notably, a large statistical decrease 
in microglial population was observed in the cerebellum of GFAP-IL6 Tenilsetam treated mice when 
compared to GFAP-IL6 control mice (Fig. 8d). This indicates that Tenilsetam treatment decreases chronic 
neuroinflammation and therefore reduces neuronal degradation after 5 months of feeding. 
The cerebellar volume of each control and variable group in the Tenilsetam testing cohort was 
estimated at both 8 and 18 months of age. GFAP-IL6 Tenilsetam treated mice had a significantly higher 
cerebellar volume that C57/B6 mice and GFAP-IL6 mice fed standard food pellets at 8 months of age. No 
significant difference was observed between C57/B6 and GFAP-IL6 control groups (Fig. 9). This suggests 




IL6 mice showed a significantly smaller cerebellar volume than the C57/B6 control group (Fig. 10). This 
suggests age-dependent cerebellar atrophy in the GFAP-IL6 mice. However, no statistical significance was 
observed between GFAP-IL6 treated and GFAP-IL6 control group, this suggests long term Tenilsetam 
treatment was not effective in preventing the effects of chronic neuroinflammation on cerebellar volume in 
18-month-old GFAP-IL6 mice. 
Although this study was relatively small, with between 3 and 6 mice per testing group, the results 
collected from this study did show a decrease in Iba-1+ microglia numbers in the cerebellum of 8-month-old 
GFAP-IL6 mice after 5 months of Longvida curcumin feeding, compared to GFAP-IL6 mice left untreated 
(Fig. 12d). This indicates that Longvida curcumin has an anti-inflammatory effect via the prevention of 
neuronal tissue loss due to chronic neuroinflammation. This coincides with a host of relevant literature, one 
such study investigated how curcumins in vivo anti-inflammatory and anti-oxidant capacity is due to its 
inhibitory actions on various inflammatory cytokines, kinases, transcription factors, and toxic protein 
aggregations. Tg2576 mice which express human amyloid precursor protein along with Swedish double 
mutations APPK670/671L were treated with low and high concentration doses of curcumin and it was found 
to significantly suppress microgliosis in the brain and reduced levels of oxidised proteins, IL-1𝛽, and amyloid 
peptides and plaques. Low dose curcumin was also observed to reduce astroglial marker GFAP(82). 
Ray and Lahiri (2009) investigated the in vitro neuroprotective effects of curcumin using Luminescent 
based cell Titor Glo (CTG) assays. The study demonstrated increased neuronal cell viability when comparing 
curcumin dose concentrations using differentiated rat neuronal pheochromocytome cells in the PC12 line(73). 
Another in vitro study showcased the anti-inflammatory processes of curcumin in cell culture media by 
increasing microglial cell viability and reducing induced levels of protein and mRNA for pro-inflammatory 
cytokines such as IL-6, IL-1β, and TNF-α in a time and dose-dependent regime following Aβ42 treatment. 
Shi et al (2015) also observed curcumin to inhibit the MAPK signaling cascade(83). As outlined, curcumin has 




effects of Longvida curcumin illustrates that it is significantly efficacious in reducing microglial numbers in 
the cerebellum of 8-month-old GFAP-IL6 mice, and therefore supports the hypothesis that Longvida curcumin 
is effective at reducing chronic neuroinflammation.  
The cerebellar volume of 8-month-old Longvida curcumin fed mice were stereologically calculated, 
no statistical significance was observed between any control or variable group (Fig. 13). From these results, 
it can be concluded that Longvida curcumin has no effect on cerebellar volume after 5 months of treatment. 
When directly comparing the efficacy of Tenilsetam and Longvida curcumin on reducing Iba-1+ 
microglia in the cerebellum of 8-month-old mice, no statistical significance can be observed between both 
C57/B6 control groups (Fig. 14a). This indicates that the general health and breeding of the C57/B6 are 
consistent between research projects and it also provides a clear, consistent baseline of healthy microglial 
numbers in the cerebellum of mice that do not suffer from chronic neuroinflammation. 
One notable observation is the significant difference in total microglial numbers between Tenilsetam 
and Longvida curcumin GFAP-IL6 control groups, which is clearly illustrated in Fig. 14b. GFAP-IL6 mice in 
the Tenilsetam cohort are exhibiting total microglial population numbers in the cerebellum in excess of 
1,500,000, whereas the Longvida curcumin counterpart is showing an average of 500,000 microglia in the 
cerebellum. One probable explanation for the considerable decrease in microglial numbers in the Longvida 
curcumin cohort is the breeding selection process. The healthiest mice of each generation are generally chosen 
to reproduce, as a result, each generation of GFAP-IL6 mice bred are healthier and experience less aggressive 
chronic neuroinflammation than the previous generation. This effect can become more apparent when 
comparing two cohorts separated by multiple generations as illustrated in Fig. 15. 
Another comparison that can be performed between Tenilsetam and Longvida curcumin is between 
the cerebellum of each treated group. A statistical significance is observed between Tenilsetam and Longvida 




cohort exhibiting lower total numbers of Iba-1+ microglia in the cerebellum (Fig. 15), it is difficult to attribute 
the significant decrease in total microglial numbers specifically due the anti-inflammatory effects of Longvida 
curcumin in the CNS. Other factors such as breeding patterns can affect mouse health and therefore microglial 
numbers. Future research investigating the effects of breeding patterns on genetic variability altering the 
degree of chronic neuroinflammation can be performed to further elucidate the total impact on microglial 
numbers in the mouse brain. 
The final comparison that can be made between the two compounds is the effect they have on 
cerebellar volume in 8-month-old mice. 2-way-ANOVA analysis shows no statistical difference between 
cerebellar volume in Tenilsetam and Longvida curcumin-treated cohorts (Fig. 16). This suggests that both 
drug treatments are as efficacious as each other in preventing cerebellar atrophy in 8-month-old mice. 
6.1 Impact 
AD is one of the most common types of neurodegenerative diseases, accounting for an estimated 60 
to 80% of all dementia cases(36). In the world, 47 million people live with dementia, and this number is 
estimated to increase to an alarming 131 million by the year 2050. This has a huge socio-economic impact, 
with the estimated cost of dementia reaching a staggering US $818 billion. In Australia, it is the single greatest 
cause of disability in the aging population, affecting more than 300,000 Australians. Members of younger 
generations may also experience some form of AD, even if it is the mildest form of pre-clinical AD. These 
unfortunate individuals are commonly found in scenarios where significant head trauma has occurred, whether 
through car accidents or through occupation/hobbies i.e. athletes of high contact, low protection sports. 
Efficacious CSAIDs such as Longvida curcumin and Tenilsetam can be adopted as a preventative lifestyle 
measure such as introducing them into a diet or multi-vitamin plan which could be utilised synergistically 
with other preventative treatment plans. This will have a tremendous positive impact on not only AD but also 





As this was a pilot study, there were many limiting factors in this study that could not be avoided or 
amended. One such limiting factor was the amount of time that was available to acquire preliminary results. 
Due to the limited time available to complete this project, the study was relatively brief, spanning over 8 
months while compared to other studies which may run over a 12-18 month period. However, there are some 
variables which are unavoidable when testing, these include unknown changes to animal food, either by animal 
facility staff or via the supplying company, changes to staffing of the animal facility causing inconsistencies 
with protocol, also new staff members introduce novel smells and sounds which may have altered stress levels 
in the mice. 
Studies have shown that chronic neuroinflammation can be attributed to a decrease in cognitive and 
motor function. Mice degenerate further as they are exposed to constantly higher levels of inflammation as 
time passes, however, the highest rate of microglial occurrence is within the first 3 month period. It is possible 
that due to peak neuroinflammation and therefore microglial counts, the impact of Longvida curcumin and 
Tenilsetam on Iba-1+ microglial cell counts may not be statistically useful in determining any difference. It is 
plausible to infer that allowing the mice to mature over longer periods of time i.e. 12 and 18 months would 
aid in producing a discernible difference in microglial estimates between variables. 
Another limiting factor in this study was the availability of mice, although gestation periods for mice 
are relatively short ranging between 18 – 22 days(27), there is a limited number of mice born per litter. These 
mice are then categorised into in C57/B6 control and treated and  GFAP-IL6 control and treated mice which 
are distributed among the lab, it is arguable that the small sample size of three to six mice per cohort is too 
small to achieve statistically robust results for this project, however, similar pilot studies have produced 




One possibility which may have been partially responsible for the decrease in the stereological 
estimates of the microglial population was user error. With multiple research streams using GFAP-IL6 mice, 
some spanning over many years, multiple researchers are tasked to complete the stereological estimates. With 
each individual researcher comes a slightly different technique of counting. This encompasses how each 
researcher determines the SRS grid layout, counting frame size and possibly the most important aspect of 
counting; what is identified as a microglial cell to count for each immunohistochemical stain such as Iba-l, 
TSPO, GFAP, and their fluorescent counterparts. To negate this issue, it would be ideal to have only one 
individual completing the stereological estimates for the lab at all times. This would ensure that each estimate 
would be consistently counted the same as the last, improving the overall quality of the stereological counts 
in the lab. However, stereological counting is a laborious and repetitive technique used for estimation and, as 
a result, it is not feasible for a single individual to complete all of the required counting. Completion by only 
one single individual could lead to lapses in concentration and ultimately compromise the consistency of 
results. One way to minimise result inconsistencies is to assign one researcher to complete all of the 
stereological counting within a research project and, if possible, any others. Reducing the number of people 
counting microglial cells between research projects will decrease inconsistencies between results. Conversely, 
another way to reduce counting errors could be to conduct practice counting during training with a known 
volume and population of microglia. This would act as a standard that every new researcher must count and 
achieve an accurate estimated population number using weighted section thickness with an acceptable 
coefficient error. 
The GFAP-IL6 mouse model does have some limitations. The levels of IL-6 encoded transgene 
cytokine in the brain of transgenic mice, which is a crucial element of neuroinflammatory mouse models, may 
not be within human-relevant physiopathological or physiological ranges to accurately equate(84). Secondary 
to physiopathological IL-6 levels in mouse brains, a major concern with this model is that it is too simple to 




individual will experience over an average human lifetime of 80 years. Ultimately, this means that the sporadic 
AD in humans may be less responsive to CSAID treatment compared to AD induced in transgenic animal 
models. Although this may be true to some degree, there is currently no other mouse model that can humanely 
and accurately represent chronic neuroinflammation like the GFAP-IL6 model, therefore, making the best 
parallel to work with until future human clinical trials. 
Genetic diversion found when comparing laboratory inbred rodent colonies has a significant impact 
on future biological experimental design, outcome and reproducibility(85). The introduction of the B6 colony 
into the C57 and transgenic mouse lineage may have increased the rate of SNPs and polygenic polymorphisms 
to occur, some of which may have affected the inflammation rate in the CNS of the GFAP-IL6 mouse. 
Limiting genetic drift between generations will assist in keeping test procedures and results consistent, 
however involuntary genomic drift is difficult to predict or prevent from occurring. Furthermore, any 
bottleneck or founder effects have a higher incidence rate as the animals are transported between colonies 
used to institute a new colony or to reobtain an old colony. Therefore, it is reasonable to expect colonies even 
of the same species and strain to vary genetically(50). 
Another factor that was limited by time and mouse availability was treatment group variability. Upon 
conclusion of the Longvida curcumin testing, only mice treated with Longvida curcumin (C57/B6 treated and 
GFAP-IL6 treated) were stereologically assessed. Similar control groups such as C57/B6 mice untreated and 
GFAP-IL6 untreated can be added to aid in higher detailed statistical analysis within the Longvida curcumin 
study and when comparing Longvida curcumin treated mice to Tenilsetam treated mice. 
Finally, this pilot study assessed the therapeutic effect of Longvida curcumin in chronically 
neuroinflamed mice, however, it did not include any behavioural or memory testing to show any potential 
cognitive performance benefits Longvida curcumin may catalyse. Based on observations from unpublished 




than GFAP-IL6 mice that were left untreated with Longvida curcumin. Future studies will increase group 
testing size include behavioural testing to illustrate with increased detail any cognitive changes treated mice 
develop. 
Other limiting issues include human resources, housing space, and cost. Limited funding is provided 
for a Master level research project, this ultimately reduces the maximum number of mice that could be used 
per study. Finding an appropriate number of mice to be used per study, affordable housing costs and project 
timeline must be considered for future studies. 
6.3 Future Work 
This research project aimed at developing a greater understanding of the cognitive effects of Longvida 
curcumin and Tenilsetam Iba1+ microglial cells in the cerebellum through stereological estimation. Stereology 
can provide acceptable results; however, the results may vary depending on counting frame size and SRS grid 
layout. Future scientific method must include more accurate and precise measurements of neuroinflammation. 
Two techniques that may be used that do not rely on stereological estimates are Quantitative Polymerase Chain 
Reaction (qPCR) and Enzyme-Linked Immunosorbent Assay (ELISA) Cytokine array. 
qPCR also known as Real-Time PCR (RT-PCR) can be used to accurately quantify and compare gene 
copy number variations (CNV’s) between C57/B6 and GFAP-IL6 mice and be able to identify any CNV 
changed due to CSAID exposure. CNV quantification of both cohorts will help elucidate any potential genetic 
variation that may be causing a decrease in microglial expression through the up-regulation and/or down-
regulation of specific genes. To perform qPCR, normalisation with reference housekeeping genes is necessary, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hypoxanthine ribosyltransferase (HPRT)(86) can 
be used as stable reference genes for transcription in the 5’-3’ and 3’-5’ direction. Once housekeeping genes 




followed to isolate RNA, synthesise cDNA, perform qPCR, determine the efficiency of the qPCR and perform 
statistical analysis on the data to quantify CNVs.  
Genomic studies have also identified genes: CLU, CR1, and TREM2 as pro-inflammatory factors that 
increase the risk of developing AD(26). Future work could include searching for the upregulation of any of 
these genes to indicate the ELISA cytokine arrays can be used in future experimentation to quantify the 
concentration of many cytokines in both inbred and cross-bred cohorts. IL-6, IL-1β, and TNF-α are cytokines 
that have been linked to neuroinflammation(39-41), ELISA assay such as Quantibody® Mouse Cytokine 
Antibody Array 1000 will give a precise concentration measurement of these and many other cytokines. These 
results can then be used to expound cytokine expression between Longvida curcumin and Tenilsetam cohorts. 
One other variable which may be of interest to control is the gender of the mice used in each cohort.  
Oestrogen and IL-6 have been observed to interact, reports show inhibitory effects of oestrogen on IL-6 
production(88-90), a synergistic response between the interaction of IL-6 and oestrogens on upregulating 
specific neuropeptide receptors such as oxytocin receptor(91) and cross-communication between oestrogens 
and STAT3 (IL-6 intracellular signalling molecule) in the hypothalamus(92). Although direct links between 
gender and neuroinflammation have not been found, in the interest of consistency within each variable and 
cohort, an equal number of male and female mice should be maintained until future studies with hormone 
replacement and gonadectomised animals can be carried out to resolve any gender-specific regulation(93). 
Finally, the stereological counting performed in the Longvida curcumin focused solely on Iba1+ 
microglial cells in the cerebellar region at 8 months of age, however, significant concentrations of microglial 
expression has also been observed in the hippocampus of mice(9) and at different time points. Estimations of 
Iba-1+ microglia in the cerebellum at 18 months of age and Iba-1+ microglia in the hippocampus at 8 and 18 
months of age were precluded due to time constraints imposed by the labor-intensive stereological technique. 




at multiple time points, this will give greater insight into the degree of neuroinflammation throughout multiple 
areas of the mouse brain at different time points; this will, in turn, provide further comparisons between age, 
area of the brain and treatment type i.e. Tenilsetam vs Longvida curcumin. 
Upon the success of these pilot studies, the experiment can be upscaled to a minor research study. This 
will include an increase in sample size that may provide further evidence to support the hypothesis that 
Longvida curcumin and Tenilsetam decrease the total number of Iba-1+ microglia in the cerebellum of GFAP-
IL6 mice. In the next two to three years, the minor research studies could be increased to largescale clinical 
research studies spanning over approximately two years, depending on the average lifespan of the mice, to 
further the understanding of each variable and how they play a role in decreasing microglial counts. The data 
collected, and the information learned can potentially delay the onset of neurodegenerative diseases such as 
AD in the future.  
7. Conclusion 
This research project found that Tenilsetam decreased the total number of TSPO+ microglia in the 
hippocampus of 8-month-old GFAP-IL6 mice along with Iba1+ microglia in the cerebellum and hippocampus 
of GFAP-IL6 mice at 8 months of age and in the cerebellum at 18 months of age. Microglial density in the 
cerebellum of GFAP-IL6 mice decreased to a similar level after both 5 and 15 months of feeding, with volume 
loss prevented in by Tenilsetam at 8 months.  
Longvida curcumin was found to decrease the total number of Iba-l+ microglia in the cerebellum of 
GFAP-IL6 mice at 8 months of age. When compared to Tenilsetam, Longvida curcumin had statistically 
similar Iba-1+ microglial numbers in the cerebellum of GFAP-IL6 mice at 8 months of age. Comparing these 
results and considering the efficacy of Tenilsetam, it can be inferred that due to the similarity in microglial 
population within the same genotype, Longvida curcumin is as effective as Tenilsetam at preventing 
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9.1 Article 1: Investigation into the Effects of Tenilsetam on Markers of Neuroinflammation in 
GFAP-IL6 Mice 
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9.2 Table 1: Stereological counts of TSPO+ microglia in the cerebellum and cerebellar volume of 8 and 18-month-old mice treated with Tenilsetam 
 









































































8 month C57/B6 control
3608 TSPO.DATTSPO 174 12 Cerebellum 116 0.0 20.6 n/a 130369.02 133753.77 131280.11 0.08 0.08 0.096 0.076 10000.0 1000000.0
3712 TSPO.DATTSPO 192 12 Cerebellum 131 0 22.1 n/a 169930.83 172503.92 171440.02 0.1 0.07 0.088 0.072 10000 1000000
3607 TSPO.DATTSPO 229 11 Cerebellum 141 0.0 21.6 n/a 179821.94 180402.47 181476.53 0.08 0.07 0.092 0.066 10000.0 1000000.0
3718 TSPO.DATTSPO 426 12 Cerebellum 140 0.0 25.2 n/a 358296.91 357440.63 355386.69 0.05 0.05 0.073 0.048 10000.0 1000000.0
8 month GFAP IL-6 control
3620 TSPO.DATTSPO 131 12 Cerebellum 115 20.0 25.2 322461.53 406039.28 410111.44 408640.16 0.10 0.09 0.092 0.087 2500.0 1000000.0
3621 TSPO.DATTSPO 129 10 Cerebellum 127 0.0 26.3 n/a 452223.66 452819.25 455573.41 0.10 0.09 0.093 0.088 2500.0 1000000.0
3622 TSPO.DATTSPO 163 11 Cerebellum 124 0.0 22.3 n/a 506226.75 514693.69 516341.09 0.12 0.08 0.076 0.078 2500.0 1000000.0
3623 TSPO.DATTSPO 158 10 Cerebellum 116 0 21 n/a 590947.69 598359.69 595777.56 0.07 0.08 0.077 0.08 2500 1000000
3822 TSPO.DATTSPO 306 11 Cerebellum 140 0.0 24.1 n/a 1123903.38 1124983.88 1110521.38 0.06 0.06 0.076 0.057 2500.0 1000000.0
8 month GFAP IL-6 Tanilsitam Fed
3512 TSPO.DATTSPO 261 13 Cerebellum 159 0.0 31.4 n/a 749267.31 750560.81 757302.69 0.06 0.06 0.054 0.062 2500.0 1000000.0
3513 TSPO.DATTSPO 398 12 Cerebellum 159 0.0 29.1 n/a 1057499.63 1057376.13 1077028.13 0.05 0.05 0.061 0.050 2500.0 1000000.0
3516 TSPO.DATTSPO 339 11 Cerebellum 143 0.0 29.6 n/a 1148588.63 1178458.88 1186674.13 0.06 0.05 0.070 0.054 2500.0 1000000.0
3517 TSPO.DATTSPO 285 13 Cerebellum 156 0.0 35.4 n/a 827508.81 829073.81 821673.63 0.06 0.06 0.062 0.059 2500.0 1000000.0
18 month C57/B6 control
3229 TSPO.DATTSPO 329 12 Cerebellum 167 0.0 40.0 n/a 309824.91 310793.28 309338.72 0.07 0.06 0.058 0.055 10000.0 1000000.0
3230 TSPO.DATTSPO 217 9 Cerebellum 119 0.0 34.1 n/a 155847.97 156280.95 157894.64 0.09 0.07 0.070 0.068 10000.0 1000000.0
3231 TSPO.DATTSPO 249 11 Cerebellum 150 0.0 38.7 n/a 226977.73 231567.28 230493.00 0.08 0.06 0.071 0.063 10000.0 1000000.0
18 month GFAP IL-6 Control
2821 TSPO.DATTSPO 216 12 Cerebellum 113 0.0 28.6 n/a 658810.19 656373.19 662720.25 0.06 0.07 0.080 0.068 2500.0 1000000.0
2823 TSPO.DATTSPO 213 12 Cerebellum 118 0.0 28.5 n/a 693983.06 719596.88 710651.38 0.10 0.07 0.081 0.069 2500.0 1000000.0
2825 TSPO.DATTSPO 231 10 Cerebellum 97 0.0 31.8 n/a 783798.19 788394.13 782373.19 0.07 0.07 0.082 0.066 2500.0 1000000.0
18 month GFAP IL-6 Tanilsitam Fed
2631 TSPO.DATTSPO 191 7 Cerebellum 93 0.0 29.7 n/a 605910.81 616467.94 590692.56 0.07 0.07 0.097 0.072 2500.0 1000000.0
2632 TSPO.DATTSPO 202 12 Cerebellum 115 0.0 34.4 n/a 716526.38 705784.69 700892.50 0.08 0.07 0.091 0.070 2500.0 1000000.0




9.3 Table 2: Stereological counts of TSPO+ microglia in the hippocampus and hippocampal volume of 8 and 18-month-old mice treated with 
Tenilsetam 
 














































































8 month C57/B6 control
3607 TSPO.DATTSPO 187 9 Hippocamppus 58 0.0 16.8 n/a 157129.20 160301.52 158309.97 0.09 0.07 0.070 0.073 10000.0 1000000.0
3608 TSPO.DATTSPO 162 9 Hippocamppus 60 0.0 16.0 n/a 129495.28 129482.21 129407.54 0.08 0.08 0.074 0.079 10000.0 1000000.0
3712 TSPO.DATTSPO 195 11 Hippocamppus 74 0.0 17.7 n/a 144966.41 145240.80 144353.69 0.07 0.07 0.066 0.072 10000.0 1000000.0
3718 TSPO.DATTSPO 405 9 Hippocamppus 62 0.0 17.3 n/a 294555.78 294555.78 294170.53 0.07 0.05 0.051 0.050 10000.0 1000000.0
8 month GFAP IL-6 control
3822 TSPO.DATTSPO 126 10 Hippocamppus 48 0.0 16.3 n/a 402733.31 409629.19 410333.25 0.09 0.09 0.073 0.089 3600.0 1500000.0
3623 TSPO.DATTSPO 171 10 Hippocamppus 38 0.0 17.4 n/a 188138.81 188189.91 187379.95 0.08 0.08 0.096 0.076 10000.0 1500000.0
3622 TSPO.DATTSPO 200 10 Hippocamppus 44 0.0 18.3 n/a 230658.41 232240.52 232468.33 0.09 0.07 0.074 0.071 10000.0 1500000.0
3621 TSPO.DATTSPO 166 10 Hippocamppus 37 0.0 16.8 n/a 176232.97 176232.97 177132.61 0.09 0.08 0.100 0.078 10000.0 1500000.0
3620 hippocampus.DATTSPO 181 9 Hippocamppus 44 0.0 16.8 n/a 191907.70 191907.70 191314.78 0.08 0.07 0.067 0.074 10000.0 1500000.0
8 month Tanilsetam treated GFAP-IL-6
3512 TSPO.DATTSPO 274 12 Hippocamppus 63 0.0 17.7 n/a 306619.00 306400.81 308943.16 0.06 0.06 0.066 0.060 10000.0 1500000.0
3513 TSPO.DATTSPO 227 10 Hippocamppus 60 0.0 17.9 n/a 256592.41 256486.14 254204.27 0.07 0.07 0.069 0.066 10000.0 1500000.0
3516 TSPO.DATTSPO 252 11 Hippocamppus 61 0.0 17.5 n/a 278553.84 277688.00 277594.75 0.07 0.06 0.080 0.063 10000.0 1500000.0
3517 TSPO.DATTSPO 177 11 Hippocamppus 53 0.0 18.5 n/a 206733.58 205949.50 205856.53 0.09 0.08 0.077 0.075 10000.0 1500000.0
18 month C57/B6 control
3229 tspo.DATTSPO 94 11 Hippocamppus 54 0.0 18.9 n/a 329054.50 330978.22 327990.88 0.10 0.10 0.103 0.103 3600.0 1500000.0
18 month GFAP IL-6 control
2821 TSPO.DATTSPO 163 12 Hippocamppus 58 0.0 19.2 n/a 473272.22 499565.13 501098.63 0.07 0.08 0.065 0.078 3600.0 1500000.0
2823 TSPO.DATTSPO 140 10 Hippocamppus 59 0.0 16.6 n/a 387273.28 394458.59 401908.59 0.09 0.08 0.080 0.085 3600.0 1500000.0
2825 TSPO.DATTSPO 155 13 Hippocamppus 68 0.0 19.2 n/a 496083.66 507987.91 515491.88 0.10 0.08 0.079 0.080 3600.0 1500000.0
18 month Tanilsetam treated GFAP IL-6
2631 TSPO.DATTSPO 128 10 Hippocamppus 50 0.0 16.9 n/a 399528.56 400000.28 400703.91 0.09 0.09 0.060 0.088 3600.0 1500000.0
2632 TSPO.DATTSPO 137 11 Hippocamppus 52 0.0 17.8 n/a 406814.09 405454.94 407000.19 0.08 0.09 0.067 0.085 3600.0 1500000.0




9.4 Stereological counts of Iba-1+ microglia in the cerebellum and cerebellar volume of 8-month-old mice treated with Longvida 














































































8 month C57/B6 control
3783 Iba1.DATIba1 362 12 cerebellum 181 0.0 23.3 n/a 229809.50 229674.50 231474.66 0.06 0.05 0.046 0.053 10000.0 1000000.0
3786 Iba1.DATIba1 250 11 cerebellum 135 0.0 19.6 n/a 163696.11 164331.81 167908.36 0.07 0.06 0.063 0.063 10000.0 1000000.0
3880 Iba1.DATIba1 291 10 CEREBELLUM 137 0.0 21.9 n/a 165974.66 167870.77 171294.81 0.07 0.06 0.060 0.059 10000.0 1000000.0
3883 Iba1.DATIba1 232 12 cerebellum 142 0.0 22.9 n/a 66336.82 69873.05 70165.01 0.12 0.07 0.089 0.066 10000.0 1000000.0
8 month C57/B6 LONGVIDA FED
3781 Iba1.DATIba1 311 11 cerebellum 158 0.0 21.8 n/a 203375.63 203367.23 205293.03 0.07 0.06 0.060 0.057 10000.0 1000000.0
3782 Iba1.DATIba1 355 10 cerebellum 167 0.0 23.5 n/a 238140.31 238493.84 238710.03 0.06 0.05 0.050 0.053 10000.0 1000000.0
3784 Iba1.DATIba1 287 11 cerebellum 150 0.0 21.0 n/a 201277.28 201168.06 204440.03 0.06 0.06 0.060 0.059 10000.0 1000000.0
3785 Iba1.DATIba1 360 10 cerebellum 179 0.0 21.2 n/a 254624.00 254204.13 256000.08 0.07 0.05 0.049 0.053 10000.0 1000000.0
3879 Iba1.DATIba1 381 11 cerebellum 161 0.0 22.7 n/a 225191.78 225665.58 227268.19 0.07 0.05 0.040 0.051 10000.0 1000000.0
3987 Iba1.DATIba1 338 11 cerebellum 173 0.0 22.3 n/a 205575.34 205833.19 207568.63 0.07 0.06 0.057 0.054 10000.0 1000000.0
8 month GFAP-IL6 control
3817 Iba1.DATIba1 530 9 Cerebellum 146 0.0 20.5 n/a 408046.59 421648.13 407913.69 0.06 0.04 0.059 0.043 10000.0 1000000.0
3818 Iba1.DATIba1 417 9 cerebellum 144 0.0 27.3 n/a 195209.78 195338.08 198624.91 0.10 0.05 0.064 0.049 10000.0 1000000.0
3985 Iba1.DATIba1 977 10 cerebellum 157 0.0 38.6 n/a 647332.13 646587.13 651137.06 0.04 0.03 0.046 0.032 10000.0 1000000.0
3986 Iba1.DATIba1 582 10 cerebellum 129 0.0 33.9 n/a 455866.69 455866.69 447497.38 0.06 0.04 0.056 0.041 10000.0 1000000.0
3989 Iba1.DATIba1 459 10 cerebellum 143 0.0 27.6 n/a 281401.97 282562.34 283334.38 0.05 0.05 0.060 0.047 10000.0 1000000.0
3990 Iba1.DATIba1 865 10 cerebellum 173 0.0 33.8 n/a 473825.81 473825.81 475682.56 0.05 0.04 0.039 0.034 10000.0 1000000.0
3991 Iba1.DATIba1 801 10 cerebellum 134 0.0 31.7 n/a 491573.88 491968.97 492257.34 0.06 0.04 0.051 0.035 10000.0 1000000.0
8 month GFAP-IL6 LONGVIDA FED
3815 Iba1.DATIba1 524 9 cerebellum 139 0.0 27.0 n/a 292269.13 292007.94 295312.78 0.07 0.05 0.053 0.044 10000.0 1000000.0
3816 Iba1.DATIba1 567 11 cerebellum 178 0.0 26.0 n/a 305399.19 306156.69 303945.56 0.05 0.04 0.051 0.042 10000.0 1000000.0
3987 Iba1.DATIba1 430 10 cerebellum 121 0.0 22.2 n/a 318581.50 319106.13 307296.91 0.05 0.05 0.061 0.048 10000.0 1000000.0
3988 Iba1.DATIba1 539 11 cerebellum 187 0.0 31.0 n/a 371175.25 371616.44 367195.63 0.05 0.04 0.051 0.043 10000.0 1000000.0
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